Latest News
Calculus Capital invests in Axol Bioscience following merger with Censo Biotechnologies
Biotech sector-leaders combine tools, talent, and technologies to drive life science discovery forward Merger accompanied by £3.8million ($5.3m USD) investment across existing shareholders and new investors, which will be used to fund recruitment and growth of the business Axol Bioscience Ltd, an established provider of stem cells produced from reprogrammed human blood and tissue cells, … Continued
Spotlight On: Axol Bioscience
As part of our ‘Spotlight On’ series, we focus on Axol Bioscience, a company who provides human cell culture systems for medical research, disease modelling and drug development. Axol Bioscience supplies high quality human cells, both healthy and diseased, to many of the world’s biggest pharmaceutical companies and best known research institutions. Axol generates stem … Continued
Axol Bioscience introduces Human iPSC-derived Atrial Cardiomyocytes
Calculus Capital portfolio company, Axol Bioscience Ltd., has launched their Human iPSC-derived Atrial Cardiomyocytes for the discovery and development of novel treatments and advancing our understanding of cardiovascular disease. As a human cell culture specialist they already provide custom services for disease modelling and drug discovery markets. Generated from the same donor as Axol’s highly validated … Continued
Calculus Capital invests £2.5m in Axol Bioscience
Calculus Capital invests £2.5m in Axol Bioscience Private equity firm Calculus Capital, a leading EIS and VCT investor, has completed its third deal in two weeks, investing £2.5m in Cambridge-based Axol Bioscience (Axol), a provider of stem cells produced from reprogrammed human blood and tissue cells. Axol supplies high quality human cells especially live human … Continued